FDA Vaccine and Biotech Chief Dr. Vinay Prasad LEAVES Agency for SECOND Time in Under a Year
The Food and Drug Administration (FDA) has confirmed that Dr. Vinay Prasad is leaving the agency for the second time in less than a year.
Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER), will depart at the end of April, with no successor named yet.
Prasad was appointed in 2025 to lead the FDA’s Center for Biologics Evaluation and Research (CBER), the division responsible for regulating vaccines, blood products, and gene therapies.
Prasad’s first departure came in July 2025, when he abruptly resigned after only a few months in the role following an explosive exposé led by investigative journalist Laura Loomer.
The Gateway Pundit reported last year that Loomer publicly exposed Prasad’s shocking anti-Trump rhetoric, far-left allegiances, and dangerous abuse of regulatory power.
“We have a crisis at the FDA! A wolf in sheep’s clothing is sabotaging President Trump’s bold “Make America Healthy Again” (MAHA) agenda!” Loomer wrote on X.
Loomer continued, “This is no mere bureaucratic misstep. It’s a catastrophic vetting failure that threatens to derail the America First healthcare revolution. Prasad’s anti-Trump rhetoric, radical left-wing ideology, and deliberate actions to obstruct our President’s deregulatory mission prove he’s a dangerous misfit. The time to act is NOW—Prasad must be REMOVED before he destroys Trump’s vision for a healthier America!”
According to Loomer:
In 2021, Prasad described himself as a “political liberal, closest to Elizabeth Warren” and a “Sanders/Warren liberal,” proudly embracing a progressive identity. He voted for Bernie Sanders in the 2016 Democratic primary, and FEC records reveal he donated to Sanders’ campaign, signaling his support for radical left-wing policies.
In 2020, Prasad declared on X that he wanted “Biden to win more than anything” and confirmed he voted against Trump, solidifying his opposition to the President.
Prasad’s policy positions are a direct affront to the conservative principles underpinning Trump’s agenda. He advocates for universal basic income, student loan forgiveness, open borders, and Roe v. Wade abortion standards. He supports a 50% marginal tax rate for high earners, a wealth tax, single-payer healthcare, universally funded pre-K and community college, and expansive parental leave policies.
[..]
Prasad’s disdain for Trump is personal and vitriolic. He has called the President “perhaps the worst president in the history of the Republic.” Prasad has claimed that Trump disagreed with him “on probably 90% of issues.” He compared Trump’s family separation immigration policy to a “human rights violation” worthy of the International Criminal Court. Prasad mocked his election fraud claims as “laughable and pathetic,” and called January 6 “a terrible day.” Further, he even attacked Trump University as a “scam.” Prasad consistently refers to the President as “orange man.” This is a derogatory jab used by the radical Left to attack Trump over his tan skin. Prasad has a strong admiration for Dr. Anthony Fauci, whom he dubbed “St. Anthony of Fauci” with “profound reverence.” Thisfurther highlights his alignment with figures Trump has criticized, particularly over the COVID-19 response.
Since assuming control of CBER at the FDA, Prasad has amassed unprecedented power. He holds three key FDA roles: Chief Medical Officer, Chief Scientific Officer, and Director of CBER. Reports suggest he is under consideration to lead the Center for Drug Evaluation and Research (CDER). This could make him more influential than FDA Commissioner Marty Makary. Moreover, this consolidation of authority in the hands of a Trump antagonist and avowed Leftist is a recipe for disaster. Prasad’s actions further demonstrate a clear intent to undermine President Trump’s vision.
Read more here.
The pressure became too much, and Prasad quietly stepped down from his roles as Chief Medical Officer, Chief Scientific Officer, and Director of the Center for Biologics Evaluation and Research (CBER).
But the exit was short-lived.
After strong support from FDA leadership and health officials, Prasad returned to the agency less than two weeks later, resuming his role overseeing vaccines and advanced biologic treatments.
Now Prasad is leaving again, this time after months of escalating disputes with biotech companies and pharmaceutical manufacturers.
FDA Commissioner Marty Makary announced the news to FDA staff in an email late Friday, saying Prasad would depart at the end of April. Makary said Prasad would return to his academic job at the University of California, San Francisco.
[…]
In the last month, Prasad has come under fire from pharmaceutical executives, investors, members of Congress and other critics for multiple decisions at the agency.
First, Prasad initially refused to allow the FDA to review a highly anticipated flu vaccine from drugmaker Moderna made with mRNA technology. The rejection of the application, highly unusual for the FDA, prompted Moderna to go public with Prasad’s decision and vow to formally challenge it.
A week after the rejection became public, the FDA reversed course and said it would accept the shot for review after all, pending an additional study from Moderna.
Then, in the past week, the FDA engaged in a highly unusual public fight with a small drug company developing an experimental treatment for Huntington’s Disease, a fatal condition that affects about 40,000 people in the U.S.
The company, UniQure, said Monday that the FDA was demanding a new trial of its gene therapy that would involve performing a sham surgery on some of the patients in the trial. The company’s gene therapy is injected directly into the brain during a surgical procedure.
Company executives said the request for a sham-controlled trial contradicted previous FDA guidance and raised ethical concerns for patients.
The post FDA Vaccine and Biotech Chief Dr. Vinay Prasad LEAVES Agency for SECOND Time in Under a Year appeared first on The Gateway Pundit.